RT Journal Article
SR Electronic
T1 710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A805
OP A805
DO 10.1136/jitc-2023-SITC2023.0710
VO 11
IS Suppl 1
A1 Cho, Byoung Chul
A1 Lee, Jae Lyun
A1 Shin, Sang Joon
A1 Shim, Byoung Yong
A1 Lee, Hyo Jin
A1 Lee, Jung-Yun
A1 Powderly, John
A1 Lee, Soohyeon
A1 Cohen, Julia
A1 Yun, Nari
A1 Ham, Mina
A1 Lee, Kyoyoung
A1 Kang, Hyunjin
A1 Pyo, Kyoung-Ho
A1 Kim, Jea Hwan
A1 Kim, Mi hyun
A1 Kim, Dong
A1 Jang, Myoung Ho
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A805.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.